Horizon Therapeutics said to be fielding $20 billion takeover interest, reveals the Wall Street Journal

Biopharmaceutical dealmaking is back in vogue and hacks at the Wall Street Journal have dug out the latest scoop.

The WSJ revealed just now that rare disease developer Horizon Therapeutics PLC has received "takeover interest" from large pharmaceutical companies.

The newspaper cautioned, though, that any tie-up is uncertain and a deal may not emerge...